Product Description: Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Kumar S, et al. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models. MAbs. 2021 Jan-Dec;13(1):1954136.
CAS Number: 2022215-59-2
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Cancer
Solubility: H2O
Target: PD-1/PD-L1